Section 5: Patient Safety and Quality Assurance

5PSQ-047

NIVOLUMAB FLAT DOSE, CLINICAL-ETHICAL AND ECONOMIC IMPLICATIONS

5PSQ-046

EFFICACY AND SAFETY OF PANITUMUMAB IN METASTATIC COLORECTAL CANCER TREATMENT

5PSQ-045

SAFETY PROFILE OF SUNITINIB IN REAL CLINICAL PRACTICE

5PSQ-044

ASEPTIC MENINGITIS INDUCED BY INTRAVENOUS IMMUNOGLOBULIN

5PSQ-043

COMORBIDITIES, POLYPHARMACY AND ADHERENCE IN GERIATRIC HIV PATIENTS

5PSQ-042

MODIFICATION ON FASTING LIPID AND RENAL PARAMETERS IN PATIENTS SWITCHING FROM TENOFOVIR DISOPROXIL TO TENOFOVIR ALAFENAMIDE

5PSQ-041

EFFICACY AND SAFETY OF CIDOFOVIR IN THE TREATMENT OF LARYNGEAL PAPILLOMATOSIS: CASE REPORTS

5PSQ-040

REAL-LIFE DIRECT-ACTING ANTIVIRALS EFFECTIVENESS COMPARATIVE STUDY IN HIV-HEPATITIS C VIRUS COINFECTED PATIENTS

5PSQ-039

GLECAPREVIR/PIBRENTASVIR ASSOCIATION FOR CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS IN HEALTH

5PSQ-038

SAFETY AND EFFECTIVENESS OF HIV POST-EXPOSURE PROPHYLAXIS

5PSQ-037

ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS POSTEXPOSURE PROPHYLAXIS IN A THIRD-LEVEL HOSPITAL

5PSQ-036

POLYPHARMACY AND DEPRESCRIBING IN HIV-INFECTED ELDERLY POPULATION

5PSQ-035

ANALYSIS OF THE MEDICATION TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA TREATED IN THE COMMUNITY AND HAVING RESULTED IN HOSPITALISATION

5PSQ-034

LINEZOLID AND SEROTONIN SYNDROME

5PSQ-033

EFFECTIVENESS OF COMPUTERISED DECISION SUPPORT SYSTEM-BASED INTERVENTION IN ANTIMICROBIAL USE: THE HIGEA PROJECT

Pages